Explore the words cloud of the CleverGenes project. It provides you a very rough idea of what is the project "CleverGenes" about.
The following table provides information about the project.
|Coordinator Country||Finland [FI]|
|Total cost||2˙437˙500 €|
|EC max contribution||2˙437˙500 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2015-11-01 to 2020-10-31|
Take a look of project's partnership.
|1||ITA-SUOMEN YLIOPISTO||FI (KUOPIO)||coordinator||2˙437˙500.00|
Background: Therapeutic angiogenesis with vascular endothelial growth factors (VEGFs) has great potential to become a novel, minimally invasive new treatment for a large number of patients with severe myocardial ischemia. However, this requires development of new technology. Advancing state-of-the-art: We propose a paradigm shift in gene therapy for chronic ischemia by activating endogenous VEGF-A,-B and -C genes and angiogenic transcription programs from the native promoters instead of gene transfer of exogenous cDNA to target tissues. We will develop a new platform technology (endogenetherapy) based on our novel concept of the release of promoter pausing and new promoter-targeted upregulating short hairpinRNAs, tissue-specific superenhancerRNAs activating specific transcription centers involving gene clusters in different chromosomal regions, small circularRNAs formed from self-splicing exons-introns that can be regulated with oligonucleotides and small molecules such as metabolites, nuclear RNAi vectors and specific CRISPR/gRNAmutatedCas9-VP16 technology with an ability to target integration into genomic safe harbor sites. After preclinical studies in mice and in a newly developed chronic cardiac ischemia model in pigs with special emphasis on the analysis of clinically relevant blood flow, metabolic and functional outcomes based on MRI, ultrasound, photoacoustic and PET imaging, the best construct will be taken to a phase I clinical study in patients with severe myocardial ischemia. Since endogenetherapy also involves epigenetic changes, which are reversible and long-lasting, we expect to efficiently activate natural angiogenic programs. Significance: If successful, this approach will begin a new era in gene therapy. Since there is a clear lack of technology capable of targeted upregulation of endogenous genes, the novel endogenetherapy approach may become widely applicable beyond cardiovascular diseases also in other areas of medicine and biomedical research.
|year||authors and title||journal||last update|
Seppo YlÃ¤-Herttuala, Andrew H. Baker
Cardiovascular Gene Therapy: Past, Present, and Future
published pages: 1095-1106, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2017.03.027
|Molecular Therapy 25/5||2019-07-05|
Johanna LÃ¤hteenvuo, Seppo YlÃ¤-Herttuala
Advances and Challenges in Cardiovascular Gene Therapy
published pages: 1024-1032, ISSN: 1043-0342, DOI: 10.1089/hum.2017.129
|Human Gene Therapy 28/11||2019-07-05|
Nihay Laham-Karam, Pia Laitinen, Tiia A. Turunen, Seppo YlÃ¤-Herttuala
Activating the Chromatin by Noncoding RNAs
published pages: , ISSN: 1523-0864, DOI: 10.1089/ars.2017.7248
|Antioxidants & Redox Signaling||2019-07-05|
Minna U. Kaikkonen, Paavo Halonen, Oscar Hsin-Fu Liu, Tiia A. Turunen, Juho Pajula, Pierre Moreau, Ilakya Selvarajan, Tomi Tuomainen, Einari Aavik, Pasi Tavi, Seppo YlÃ¤-Herttuala
Genome-Wide Dynamics of Nascent Noncoding RNA Transcription in Porcine Heart After Myocardial InfarctionCLINICAL PERSPECTIVE
published pages: e001702, ISSN: 1942-3268, DOI: 10.1161/CIRCGENETICS.117.001702
|Circulation: Cardiovascular Genetics 10/3||2019-07-05|
Iiro Hassinen, Antti KivelÃ¤, Antti Hedman, Antti Saraste, Juhani Knuuti, Juha Hartikainen, Seppo YlÃ¤-Herttuala
Intramyocardial Gene Therapy Directed to Hibernating Heart Muscle Using a Combination of Electromechanical Mapping and Positron Emission Tomography
published pages: 830-834, ISSN: 1043-0342, DOI: 10.1089/hum.2016.131
|Human Gene Therapy 27/10||2019-07-05|
Henri Niskanen, Irina Tuszynska, Rafal Zaborowski, Merja HeinÃ¤niemi, Seppo YlÃ¤-Herttuala, Bartek Wilczynski, Minna U Kaikkonen
Endothelial cell differentiation is encompassed by changes in long range interactions between inactive chromatin regions
published pages: 1724-1740, ISSN: 0305-1048, DOI: 10.1093/nar/gkx1214
|Nucleic Acids Research 46/4||2019-04-18|
Johanna P. Laakkonen, Jari P. Lappalainen, Thomas L. Theelen, Pyry I. Toivanen, Tiina Nieminen, Suvi Jauhiainen, Minna U. Kaikkonen, Judith C. Sluimer, Seppo YlÃ¤-Herttuala
Differential regulation of angiogenic cellular processes and claudin-5 by histamine and VEGF via PI3K-signaling, transcription factor SNAI2 and interleukin-8
published pages: 109-124, ISSN: 0969-6970, DOI: 10.1007/s10456-016-9532-7
Jussi Nurro, Paavo J Halonen, Antti Kuivanen, Miikka Tarkia, Antti Saraste, Krista Honkonen, Johanna LÃ¤hteenvuo, Tuomas T Rissanen, Juhani Knuuti, Seppo YlÃ¤-Herttuala
AdVEGF-B 186 and AdVEGF-D Î”NÎ”C induce angiogenesis and increase perfusion in porcine myocardium
published pages: 1716-1720, ISSN: 1355-6037, DOI: 10.1136/heartjnl-2016-309373
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CLEVERGENES" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CLEVERGENES" are provided by the European Opendata Portal: CORDIS opendata.